Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

By D. Scott, Andrew R. Bayly, Chris Abell, J. Skidmore. Nature reviews. Drug discovery, 2016

971 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials (2020, background): “Tryptophan, arginine, and tyrosine are more likely to appear in hot-spots than other amino acids.(15,30) Because of the important role of these “hot-spots” amino acids, they are often used to design PPI drugs.”
Deep learning in bioinformatics: introduction, application, and perspective in big data era (2019, background): “Understanding protein-protein interaction can be helpful for predicting the functionality of uncharacterized proteins and designing drugs [136, 130].”
Recent advances in Alzheimer’s disease: mechanisms, clinical trials and new drug development strategies (2024, background): “591 Additionally, another Keap1-Nrf2 PPI inhibitor 74 , which combined conformational features signi ﬁ cantly similar to the Keap1-Nrf2 ETGE complex, revealed the unique inhibition mechanism and provided an innovative strategy for the development of new Keap1-Nrf2 PPI inhibitors.”